We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

231 hedge funds and large institutions have $3.86B invested in Neurocrine Biosciences in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 67 increasing their positions, 96 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

496% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $13.9M

91% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 22

12% more capital invested

Capital invested by funds: $3.44B → $3.86B (+$423M)

9% more funds holding

Funds holding: 212 → 231 (+19)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

30% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 96

Holders
231
Holders Change
+19
Holders Change %
+8.96%
% of All Funds
6.16%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.19%
New
42
Increased
67
Reduced
96
Closed
22
Calls
$82.9M
Puts
$13.9M
Net Calls
+$69M
Net Calls Change
+$62.4M

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$44.1M
2
SIG
Senator Investment Group
New York
+$39.1M
3
American Century Companies
American Century Companies
Missouri
+$34M
4
JP Morgan Chase
JP Morgan Chase
New York
+$27.2M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$23.6M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$85.6M
2
BFA
BlackRock Fund Advisors
California
-$58.9M
3
Citadel Advisors
Citadel Advisors
Florida
-$40.4M
4
O
OrbiMed
New York
-$38.6M
5
Invesco
Invesco
Georgia
-$35.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
101
DAFNA Capital Management
California
$3.43M -$36.7K -797 -1%
TA
102
Teachers Advisors
New York
$3.29M -$7.03M -152,760 -68%
BlackRock
103
BlackRock
New York
$3.28M +$380K +8,247 +13%
MOACM
104
Mutual of America Capital Management
New York
$3.27M +$9.21K +200 +0.3%
PPA
105
Parametric Portfolio Associates
Washington
$3.21M +$1.05M +22,781 +48%
Lazard Asset Management
106
Lazard Asset Management
New York
$3.08M +$3.12M +67,684 New
ProShare Advisors
107
ProShare Advisors
Maryland
$3.05M -$415K -9,021 -12%
Squarepoint
108
Squarepoint
New York
$3M +$3.03M +65,900 New
Morgan Stanley
109
Morgan Stanley
New York
$2.92M +$1.24M +26,900 +72%
UOC
110
UBS O'Connor
Illinois
$2.81M -$2.39M -51,829 -46%
SEI Investments
111
SEI Investments
Pennsylvania
$2.76M +$2.32M +50,358 +482%
State of Wisconsin Investment Board
112
State of Wisconsin Investment Board
Wisconsin
$2.65M +$2.68M +58,300 New
EA
113
Emerald Acquisition
Washington
$2.65M +$2.68M +58,261 New
BG
114
Bellevue Group
Switzerland
$2.64M -$322K -7,000 -11%
LP
115
LMR Partners
United Kingdom
$2.63M +$2.66M +57,800 New
EI
116
EAM Investors
California
$2.54M -$1.17M -25,489 -31%
Ohio Public Employees Retirement System (OPERS)
117
Ohio Public Employees Retirement System (OPERS)
Ohio
$2.52M +$2.55M +55,491 New
DBG
118
De Burlo Group
Massachusetts
$2.38M – – –
AIMCA
119
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$2.28M – – –
Wells Fargo
120
Wells Fargo
California
$2.28M -$851K -18,487 -27%
NFA
121
Nationwide Fund Advisors
Ohio
$2.09M -$2.17M -47,098 -51%
Schroder Investment Management Group
122
Schroder Investment Management Group
United Kingdom
$2.06M +$2.09M +45,289 New
GH
123
GAM Holding
Switzerland
$2M -$704K -15,300 -26%
CCM
124
Cupps Capital Management
Illinois
$2M -$2.52M -54,738 -55%
PA
125
Profund Advisors
Maryland
$1.96M -$183K -3,972 -8%
3 4
5
6 7

NBIX Hedge Fund Activity: Q2 2016 in Review

231 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2016, worth a combined $3.86B — up 12% from $3.44B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new NBIX positions and 22 closed out — a net gain of 20 holders — while 67 added to existing stakes and 96 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $44.1M. The largest seller was Visium Asset Management, cutting an estimated $85.6M.

  • 231 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2016, up from 212 in Q1 2016.
  • Funds reported $3.86B of Neurocrine Biosciences stock for Q2 2016, up 12% quarter-over-quarter.
  • 42 funds opened new Neurocrine Biosciences positions in Q2 2016 and 22 closed out, a net change of +20 holders.
  • The largest Neurocrine Biosciences buyer in Q2 2016 was AllianceBernstein, an estimated $44.1M added.
  • The largest Neurocrine Biosciences seller in Q2 2016 was Visium Asset Management, an estimated $85.6M sold.

Based on aggregated 13F filings for Q2 2016.